{"id":"dabigatran-etexilate-de","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute hemorrhage","Acute nephropathy","Anemia","Blood coagulation disorder","Cerebral hemorrhage"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05788328"],"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"allNames":"dabigatran etexilate (de)","offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabig) — Healthy. Trial terminated early."}],"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"Dabigatran etexilate is a direct thrombin inhibitor anticoagulant approved to reduce stroke risk in patients with atrial fibrillation and to treat venous thromboembolism. Unlike warfarin, it works by directly blocking thrombin without requiring INR monitoring, offering a more predictable anticoagulant effect with fixed dosing.","brandName":"Dabigatran etexilate (DE)","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","novelty":"","modality":"","drugClass":"Dabigatran etexilate (DE) as oral capsule","explanation":"Dabigatran etexilate is an anticoagulant medication that prevents blood clots by targeting a specific protein in your blood called thrombin. Thrombin is a key enzyme that acts like the final trigger in the clotting cascade—it converts fibrinogen into fibrin, which forms the structural meshwork of blood clots. By directly inhibiting thrombin, dabigatran essentially stops this final step of clot formation before it can happen.\n\nWhen you take dabigatran etexilate, it's quickly converted in your body to its active form, dabigatran. This active form circulates in your bloodstream and continuously blocks thrombin molecules, preventing them from doing their job. This makes your blood less likely to form dangerous clots in the heart, veins, or arteries. The medication is particularly useful in conditions like atrial fibrillation, where irregular heartbeats create stagnant blood flow that promotes clot formation.\n\nA major advantage of dabigatran compared to older anticoagulants like warfarin is that it works predictably without requiring frequent blood tests or dietary restrictions. You take it at a fixed dose, and it provides consistent anticoagulation. However, because it works so directly and powerfully, careful monitoring for bleeding risk is still important, and it cannot be used in certain patient populations or with specific medications.","oneSentence":"Dabigatran etexilate (DE) as oral capsule","technicalDetail":""},"_companyIR":{"irUrl":"https://pfizerinc.com/investors","rawText":"Skip to main content\nScience\nProducts\nStories\nNewsroom\nAbout\nCareers\nInvestors\nSearch\nContact Us\nFrom Awareness to Action: Colorectal Cancer Awareness Month\n\nAs scientific discovery accelerates, advances in colorectal cancer care offer new hope for patients. See how Pfizer is helping reshape what's possible.\n\n \n\nExplore with us\n\n2025 Annual Review: Pfizer’s Bold Moves\n\nSharpening our science from oncology to obesity, we’re striving to expand what’s possible for those who rely on us.\n\nDiscover more\n\nLatest Articles\n\n03.27.2026\n\n|\n\nARTICLE\n\nSpotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection\n\n03.25.2026\n\n|\n\nARTICLE\n\nAs Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever\n\n03.19.2026\n\n|\n\nARTICLE\n\nPfizer Among World’s Most Ethical Companies for 5th Straight Year\n\n03.12.2026\n\n|\n\nARTICLE\n\nCEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review\n\n03.10.2026\n\n|\n","revenueRefs":[],"pipelineRefs":[]},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"dabigatran-etexilate-de","indications":{"approved":[{"name":"Deep vein thrombosis","diseaseId":"deep-vein-thrombosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","diseaseId":"prevention-of-thromboembolism-with-chronic-atrial-fibrillation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of deep vein thrombosis","diseaseId":"prevention-of-deep-vein-thrombosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of stroke","diseaseId":"prevention-of-stroke","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of systemic embolism","diseaseId":"prevention-of-systemic-embolism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary embolism","diseaseId":"pulmonary-embolism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[{"name":"Healthy","phase":"discontinued","trialId":"","patients":null,"diseaseId":"unknown","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06533280","phase":"PHASE1","title":"VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2024-08-02","conditions":"HIV Infections","enrollment":0,"completionDate":"2024-08-14","primaryEndpoint":"Part A: Number of participants with any adverse events (AEs)"},{"nctId":"NCT05068414","phase":"","title":"Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-04-12","conditions":"Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis","enrollment":122,"completionDate":"2024-09-29","primaryEndpoint":"Incidence of at least one event from the composite clinical benefit endpoints: death, non-fatal myocardial infarction, ischemic stroke, or major bleeding defined by a Bleeding Academic Research Consor"},{"nctId":"NCT05788328","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-03-27","conditions":"Healthy","enrollment":16,"completionDate":"2023-09-11","primaryEndpoint":"Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Total Dabigatran in Period 1, 4 and 7"},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708,"completionDate":"2022-03-31","primaryEndpoint":"Risk of recurrent VTE"},{"nctId":"NCT05536791","phase":"","title":"A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-11-24","conditions":"Venous Thromboembolism","enrollment":0,"completionDate":"2024-10-01","primaryEndpoint":"Incidence of any bleeding events defined as Major Bleeding Events (MBE) or Non-Major Bleeding Events (Non-MBE)"},{"nctId":"NCT02596230","phase":"","title":"RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-11-05","conditions":"Venous Thromboembolism","enrollment":7797,"completionDate":"2019-03-31","primaryEndpoint":"Objective 1: Age"}],"_emaApprovals":[{"date":"","name":"Dabigatran etexilate (DE)","holder":"","status":"Authorised","rawText":"Skip to main content\nAn official website of the European Union\nHow do you know?\n\nWe use cookies on this website. Essential cookies allow it to work properly. Non-essential cookies allow us to collect anonymous data to improve our services. You can opt out of non-essential cookies at any time.\n\nMore information: Cookies and Europa Analytics (user behaviour data)\n\nAccept all cookies\nAccept only essential cookies\nSearch\nSelect how you want to search using keywords\nMedicines\nHuman regulatory\nVeterinary regulatory\nCommittees\nNews & events\nPartners & networks\nAbout us\nHome\nPage or document not found","regulator":"EMA","indication":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"_hyperScrapedAt":"2026-03-27T21:53:02.855734","crossReferences":{"chemblId":"CHEMBL539697"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}